Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5350 - The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Motohiro Tamiya

Citation

Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260

Authors

M. Tamiya1, A. Tamiya2, K. Hosoya3, Y. Taniguchi2, T. Yokoyama4, Y. Fukuda4, K. Hirano5, H. Matsumoto5, R. Kominami6, H. Suzuki7, T. Hirashima7, J. Uchida8, M. Morita9, M. Kanazu10, N. Sawa10, S. Hara11, Y. Kinoshita11, T. Kumagai1, D. Fujimoto3

Author affiliations

  • 1 Thoracic Oncology, Osaka International Cancer Instisute, 541-8567 - Osaka/JP
  • 2 Internal Medicine, Kinki-chuo Chest Medical Center, 591-8555 - Sakai/JP
  • 3 Respiratory Medicine, Kobe City Medical Center General Hospital, 650-0047 - Kobe/JP
  • 4 Respiratory Medicine, Kurashiki Central Hospital, 710-8602 - Kurashiki/JP
  • 5 Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, 660-8550 - Amagasaki/JP
  • 6 Respiratory Medicine, Himeji Medical Center, 670-8520 - Himeji/JP
  • 7 Thoracic Oncology, Osaka Habikino Medical Center, 583-8588 - Habikino/JP
  • 8 Respiratory Medicine, Osaka General Medical Center, 558-8558 - Osaka/JP
  • 9 Respiratory Medicine, Kobe City Medical Center West Hospital, 653-0013 - Kobe/JP
  • 10 Thoracic Oncology, Osaka Toneyama Medical Center, 560-0045 - Toyonaka/JP
  • 11 Respiratory Medicine, Itami City Hospital, 664-8540 - Itami/JP

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5350

Background

Pembrolizumab (Pem) for NSCLC and PD-L1 TPS ≥50% as a first-line therapy showed the longer PFS and OS compared with chemotherapy in some clinical trial. However, only limited patients in good general condition without organ failure can participate in them and their outcomes may not be entirely representative of real-world setting.

Methods

We conducted a multicenter retrospective study across 11 medical centers (Hanshin Oncology clinical Problem Evaluation group (HOPE)). We analyzed clinical data from NSCLC patients receiving Pem as a first-line therapy between February 1st 2017 and April 30th 2018. We aimed to evaluate the efficacy and safety and to identify which patients will become more suitable candidates for Pem monotherapy.

Results

213 patients were enrolled in this study. The median age was 71 years. Out of 213 patients, 176 (82.6%) were male, 20 (9.4%) were never smokers (Median brinkman index: 900), 172 (80.8%) had ECOG PS of 0-1, 55 (25.8%) had SQ, and PD-L1 TPS were 50-74%: 97 (45.5%), 75-89%: 55 (22.1%), and 90-100%: 69 (32.4%). 39 (18.3%) of all had AEs of grades ≥3. The most frequently severe AEs was pneumonitis (10 (4.7%) including in 1 grade 4), and no patient died of severe AEs. The overall RR/DCR were 51.2%/73.2%, the median PFS/OS was 8.3/18.4 months (M). In the univariate analysis, the ECOG PS (0-1 vs. ≥2: 9.0 vs. 4.0 M, HR: 2.11, p = 0.00061), CRP/ALB (<0.3 vs. ≥0.3: NA vs. 5.9 M, HR: 1.88, p = 0.00148), and steroid usage (not usage vs. usage: 8.7 vs. 2.0 M, HR: 3.17, p = 0.00034) were significantly correlated with PFS of Pem. In the multivariate analysis, ECOG PS (0-1 vs. ≥2: HR: 1.69, p = 0.03138), CRP/ALB (<0.3 vs. ≥0.3: HR: 1.92, p = 0.00153), steroid usage (not usage vs. usage: HR: 2.94, p = 0.00267), and PD-L1 TPS (50-89% vs. 90-100%: HR: 0.65, p = 0.04984) were significantly and independently correlated with PFS of Pem.

Conclusions

Our results was consistent with the efficacy and safety of previous key clinical trials, although our study had various backgrounds. Furthermore, poor PS, high inflammatory state (CRP/ALB≥0.3), and steroid usage at the time of Pem treatment commencement were independently correlated with a shorter PFS of Pem. On the other hands, higher PD-L1 TPS (90-100%) was independently correlated with a longer PFS of Pem.

Clinical trial identification

UMIN (University Hospital Medical Information Network in Japan; number 000032470).

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

M. Tamiya: Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Taiho Pharmaceutical. A. Tamiya: Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Taiho Pharmaceutical. Y. Taniguchi: Speaker Bureau / Expert testimony: MSD. T. Yokoyama: Speaker Bureau / Expert testimony: Taiho Phermaceutical. K. Hirano: Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Taiho Phermaceutical. T. Hirashima: Speaker Bureau / Expert testimony: Taiho Phermaceutical. M. Kanazu: Speaker Bureau / Expert testimony: MSD. T. Kumagai: Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Taiho Phermaceutical. D. Fujimoto: Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Taiho Phermaceutical. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.